Evaluation of nanoscaled dual targeting drug-loaded liposomes on inhibiting vasculogenic mimicry channels of brain glioma

References

• Tang W, Fan W, Lau J, et al. Emerging blood–brain-barrier-crossing nanotechnology for brain cancer theranostics. Chem Soc Rev. 2019;48(11):2967–3014.
   PubMed Web of Science ®Google Scholar
• Weil RJ, Palmieri DC, Bronder JL, et al. Breast cancer metastasis to the central nervous system. Am J Pathol. 2005;167(4):913e20.
   Web of Science ®Google Scholar
• Wu JS, Mu LM, Bu YZ, et al. C-type natriuretic peptide-modified lipid vesicles: fabrication and use for the treatment of brain glioma. Oncotarget. 2017;8(25):40906–40921.
   PubMedGoogle Scholar
• Pollak TA, Drndarski S, Stone JM, et al. The blood–brain barrier in psychosis. Lancet Psychiatry. 2018;5(1):79–92.
   PubMed Web of Science ®Google Scholar
• Ju RJ, Zeng F, Liu L, et al. Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma. Int J Nanomedicine. 2016;11:1131–1146.
   PubMed Web of Science ®Google Scholar
• Gao Y, Yu H, Liu Y, et al. Long non-coding RNA HOXA-AS2 regulates malignant glioma behaviors and vasculogenic mimicry formation via the MiR-373/EGFR axis. Cell Physiol Biochem. 2018;45(1):131–147.
   PubMedGoogle Scholar
• Liu Y, Mei L, Yu Q, et al. Multifunctional tandem peptide modified paclitaxel-loaded liposomes for the treatment of vasculogenic mimicry and cancer stem cells in malignant glioma. ACS Appl Mater Interfaces. 2015;7(30):16792–16801.
   PubMed Web of Science ®Google Scholar
• Liu JJ, Tang W, Fu M, et al. Development of R8 modified epirubicin-dihydroartemisinin liposomes for treatment of non-small-cell lung cancer. Artif Cells Nanomed Biotechnol. 2019;47(1):1947–1960.
   PubMed Web of Science ®Google Scholar
• Belhadj Z, Ying M, Cao X, et al. Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery. J Control Release. 2017;255:132–141.
   PubMed Web of Science ®Google Scholar
• Ying X, Wen H, Lu WL, et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release. 2010;141(2):183–192.
   PubMed Web of Science ®Google Scholar
• Pang X, Wang T, Jiang D, et al. Functionalized docetaxel-loaded lipid-based-nanosuspensions to enhance antitumor efficacy in vivo. Int J Nanomedicine. 2019;14:2543–2555.
   PubMed Web of Science ®Google Scholar
• Perli G, Pessoa ACSN, Balbino TA, et al. Ionic strength for tailoring the synthesis of monomodal stealth cationic liposomes in microfluidic devices. Colloids Surf B Biointerfaces. 2019;179:233–241.
   PubMed Web of Science ®Google Scholar
• Cai D, Gao W, He B, et al. Hydrophobic penetrating peptide PFVYLI-modified stealth liposomes for doxorubicin delivery in breast cancer therapy. Biomaterials. 2014;35(7):2283–2294.
   PubMed Web of Science ®Google Scholar
• Ju RJ, Li XT, Shi JF, et al. Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer. Biomaterials. 2014;35(26):7610–7621.
   PubMed Web of Science ®Google Scholar
• Kolesnik DL, Pyaskovskaya ON, Yakshibaeva YR, et al. Time-dependent cytotoxicity of dichloroacetate and metformin against Lewis lung carcinoma. Exp Oncol. 2019;41(1):14–19.
   PubMedGoogle Scholar
• Li XY, Zhao Y, Sun MG, et al. Multifunctional liposomes loaded with paclitaxel and artemether for treatment of invasive brain glioma. Biomaterials. 2014;35(21):5591–5604.
   PubMed Web of Science ®Google Scholar
• Zhang F, Zhang CM, Li S, et al. Low dosage of arsenic trioxide inhibits vasculogenic mimicry in hepatoblastoma without cell apoptosis. Mol Med Rep. 2018;17(1):1573–1582.
   PubMed Web of Science ®Google Scholar
• Zhao M, Zhao M, Fu C, et al. Targeted therapy of intracranial glioma model mice with curcumin nanoliposomes. Int J Nanomedicine. 2018;13:1601–1610.
   PubMed Web of Science ®Google Scholar
• Angelova A, Garamus VM, Angelov B, et al. Advances in structural design of lipid-based nanoparticle carriers for delivery of macromolecular drugs, phytochemicals and anti-tumor agents. Adv Colloid Interface Sci. 2017;249:331–345.
   PubMed Web of Science ®Google Scholar
• Zerkoune L, Lesieur S, Putaux JL, et al. Mesoporous self-assembled nanoparticles of biotransesterified cyclodextrins and nonlamellar lipids as carriers of water-insoluble substances. Soft Matter. 2016;12(36):7539–7550.
   PubMed Web of Science ®Google Scholar
• Mayer LD, Tardi P, Louie AC. CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties. Int J Nanomedicine. 2019;14:3819–3830.
   PubMed Web of Science ®Google Scholar
• Punganuru SR, Madala HR, Mikelis CM, et al. Conception, synthesis, and characterization of a rofecoxib-combretastatin hybrid drug with potent cyclooxygenase-2 (COX-2) inhibiting and microtubule disrupting activities in colon cancer cell culture and xenograft models. Oncotarget. 2018;9(40):26109–26129.
   PubMedGoogle Scholar